Dimethyl fumarate Neuraxpharm Evropská unie - dánština - EMA (European Medicines Agency)

dimethyl fumarate neuraxpharm

laboratorios lesvi s.l. - dimethylfumarat - multipel sklerose, recidiverende-remitterende - immunosuppressiva - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Octreotid "Sun" 0,05 mg/1 ml injektionsvæske, opløsning Dánsko - dánština - Lægemiddelstyrelsen (Danish Medicines Agency)

octreotid "sun" 0,05 mg/1 ml injektionsvæske, opløsning

sun pharmaceutical industries europe bv - octreotidacetat - injektionsvæske, opløsning - 0,05 mg/1 ml

Sandostatin Lar 20 mg pulver og solvens til injektionsvæske, suspension Dánsko - dánština - Lægemiddelstyrelsen (Danish Medicines Agency)

sandostatin lar 20 mg pulver og solvens til injektionsvæske, suspension

novartis healthcare a/s - octreotidacetat - pulver og solvens til injektionsvæske, suspension - 20 mg

Sandostatin Lar 30 mg pulver og solvens til injektionsvæske, suspension Dánsko - dánština - Lægemiddelstyrelsen (Danish Medicines Agency)

sandostatin lar 30 mg pulver og solvens til injektionsvæske, suspension

novartis healthcare a/s - octreotidacetat - pulver og solvens til injektionsvæske, suspension - 30 mg

Locametz Evropská unie - dánština - EMA (European Medicines Agency)

locametz

novartis europharm limited  - gozetotide - radionuklidbilleddannelse - diagnostiske radioaktive lægemidler - dette lægemiddel er kun til diagnostisk brug. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.